275 related articles for article (PubMed ID: 31875587)
21. Pharmaceutical Pricing in Germany: How Is Value Determined within the Scope of AMNOG?
Lauenroth VD; Stargardt T
Value Health; 2017; 20(7):927-935. PubMed ID: 28712622
[TBL] [Abstract][Full Text] [Related]
22. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations.
DiStefano MJ; Levy JF; Odouard IC; Anderson GF
Value Health; 2023 Nov; 26(11):1618-1624. PubMed ID: 37689264
[TBL] [Abstract][Full Text] [Related]
23. Predictors of negotiated prices for new drugs in Germany.
Gandjour A; Schüßler S; Hammerschmidt T; Dintsios CM
Eur J Health Econ; 2020 Sep; 21(7):1049-1057. PubMed ID: 32451745
[TBL] [Abstract][Full Text] [Related]
24. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
Rawson NSB
J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
[TBL] [Abstract][Full Text] [Related]
25. [Benefit Assessment and Price Negotiation Under AMNOG: Calculable Process or Unfair Poker Game?].
Radic D; Haugk S; Radic M
Gesundheitswesen; 2018 Jun; 80(6):573-579. PubMed ID: 27636366
[TBL] [Abstract][Full Text] [Related]
26. [Access to medicines and South-South cooperation: a case study on joint drug price negotiations in South America].
Oliveira BNL; Oliveira MA
Cad Saude Publica; 2021; 37(10):e00170920. PubMed ID: 34730691
[TBL] [Abstract][Full Text] [Related]
27. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
28. [Establishing the value of new drugs in Italy.].
Villa F; Jommi C; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G
Recenti Prog Med; 2020 Feb; 111(2):65-69. PubMed ID: 32089554
[TBL] [Abstract][Full Text] [Related]
29. Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada.
Rawson NSB; Stewart DJ
Clinicoecon Outcomes Res; 2024; 16():437-445. PubMed ID: 38812711
[TBL] [Abstract][Full Text] [Related]
30. Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study.
Zhu H; Zhu J; Zhou Y; Shan L; Li C; Cui Y; Kang Z; Jiao M; Liu H; Gao L; Wu Q; Hao Y
Front Public Health; 2022; 10():921093. PubMed ID: 35844892
[TBL] [Abstract][Full Text] [Related]
31. Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept.
Wettstein DJ; Boes S
BMC Health Serv Res; 2021 Mar; 21(1):234. PubMed ID: 33726735
[TBL] [Abstract][Full Text] [Related]
32. Medicare Drug Price Negotiation in the United States: Implications and Unanswered Questions.
Sullivan SD
Value Health; 2023 Mar; 26(3):394-399. PubMed ID: 36503034
[TBL] [Abstract][Full Text] [Related]
33. External referencing and pharmaceutical price negotiation.
Garcia Mariñoso B; Jelovac I; Olivella P
Health Econ; 2011 Jun; 20(6):737-56. PubMed ID: 20577969
[TBL] [Abstract][Full Text] [Related]
34. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
35. Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis.
Yi H; Shi F; Wang Z; Kuai L; Xu D; Xie Y; Xing H
BMJ Open; 2023 Oct; 13(10):e064811. PubMed ID: 37852769
[TBL] [Abstract][Full Text] [Related]
36. Reforming antiretroviral price negotiations and public procurement: the Mexican experience.
Adesina A; Wirtz VJ; Dratler S
Health Policy Plan; 2013 Jan; 28(1):1-10. PubMed ID: 22375026
[TBL] [Abstract][Full Text] [Related]
37. Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China.
Ling K; Qin H; Feng Y; Che H; Ding J; Li W
Front Public Health; 2022; 10():1062736. PubMed ID: 36504948
[TBL] [Abstract][Full Text] [Related]
38. Reference pricing and price negotiations for innovative new drugs : viable policies in the long term?
Gandjour A
Pharmacoeconomics; 2013 Jan; 31(1):11-4. PubMed ID: 23329589
[No Abstract] [Full Text] [Related]
39. Does price deregulation increase drug price in China? An interrupted time series analysis.
Xiong Y; Xu J; Gao Y
Int J Health Plann Manage; 2021 Sep; 36(5):1653-1665. PubMed ID: 34028086
[TBL] [Abstract][Full Text] [Related]
40. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
Rawson NSB
Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]